4MB Stock Overview
Designs, develops, and distributes diagnostics products in the Nordic region and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Level Bio AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.021 |
| 52 Week High | SEK 0.045 |
| 52 Week Low | SEK 0.0045 |
| Beta | 0.031 |
| 11 Month Change | 22.86% |
| 3 Month Change | -4.44% |
| 1 Year Change | -45.98% |
| 33 Year Change | -91.63% |
| 5 Year Change | n/a |
| Change since IPO | -86.43% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4MB | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 0% | -4.4% | -1.9% |
| 1Y | -46.0% | -1.0% | 12.3% |
Return vs Industry: 4MB underperformed the German Life Sciences industry which returned -1% over the past year.
Return vs Market: 4MB underperformed the German Market which returned 12.3% over the past year.
Price Volatility
| 4MB volatility | |
|---|---|
| 4MB Average Weekly Movement | 44.3% |
| Life Sciences Industry Average Movement | 6.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4MB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4MB's weekly volatility has decreased from 59% to 44% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 13 | Joakim Granemo | levelbio.se |
Level Bio AB (publ) designs, develops, and distributes diagnostics products in the Nordic region and internationally. The company distributes equipment; consumables and reagents for molecular biology; and research and diagnostic products in Sweden and the Nordics. It also develops, produces, and sells products for genetic fetal diagnostics, as well as genetic miscarriage and infertility diagnostics products.
Level Bio AB (publ) Fundamentals Summary
| 4MB fundamental statistics | |
|---|---|
| Market cap | €2.22m |
| Earnings (TTM) | -€1.07m |
| Revenue (TTM) | €2.09m |
1.1x
P/S Ratio-2.1x
P/E RatioIs 4MB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4MB income statement (TTM) | |
|---|---|
| Revenue | SEK 23.74m |
| Cost of Revenue | SEK 12.28m |
| Gross Profit | SEK 11.46m |
| Other Expenses | SEK 23.63m |
| Earnings | -SEK 12.18m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 48.26% |
| Net Profit Margin | -51.30% |
| Debt/Equity Ratio | 0% |
How did 4MB perform over the long term?
See historical performance and comparison